September 10, 2019
RICHARDSON, Texas–(BUSINESS WIRE)–Fuse Medical, Inc., (OTCPK: FZMD), an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced their latest addition of orthopedic and sports medicine product offerings, the Galen Medial and Galen XT Suture Anchors, the Kopis Knotless Anchor, and the Vida Interference Screws.
The Fuse Suture Anchors are manufactured in the United States from PEEK and Titanium materials and are intended for use in the fixation of ligament, tendon, bone, or soft tissue to bone in knee, shoulder, foot/ankle, elbow, and hand/wrist procedures. The Fuse Suture Anchors are available sterile, loaded on individual inserters, and with or without integrated sutures and or needles. The single patient use, disposable instrumentation is designed to assist in reducing or eliminating facility processing costs for the sterilization of instruments.
“The addition of the Galen, Kopis and Vida Suture Anchor product lines provide Fuse Medical with a comprehensive portfolio of sports medicine and extremity offerings for soft tissue fixation,” said Christopher C. Reeg, Chief Executive Officer of Fuse Medical. “The launch of this exciting technology facilitates a more complete line of Fuse branded products within all of our specialty categories. Our goal at Fuse is to provide solutions for today’s surgical challenges and platforms to improve surgical outcomes.”
About Fuse Medical, Inc.
Fuse is an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace. Fuse provides a comprehensive portfolio of products in the orthopedic total joints, sports medicine, trauma, foot and ankle space, as well as, degenerative and deformity spine, Orthobiologics and regenerative medicine. For more information about the Company, or if you’re interested in becoming a distributor of our Fuse Suture Anchor line, or any of our other products, please contact us at firstname.lastname@example.org or visit: www.fusemedical.com.
Certain statements in this press release, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.
Fuse Medical, Inc.
Devon Morgan, Sr. Investor Relations Analyst
Office (469) 862-3030
Facsimile (469) 862-3035